US FDA questions facility design in Warning Letter for Emcure's Pune plant

By Dan Stanton contact

- Last updated on GMT

Facility design and aseptic processing procedures were high-lighted in the Warning Letter to Emcure. Image: iStock/Davizro
Facility design and aseptic processing procedures were high-lighted in the Warning Letter to Emcure. Image: iStock/Davizro

Related tags: Pharmaceutical drug, Food and drug administration

The US FDA has detailed GMP violations that prompted it to ban the importation of drugs made at an Emcure Pharmaceuticals plant in India last year. 

The US Food and Drug Administration (FDA) published details of its January 2015 visit to Emcure’s Hinjwadi, Pune facility last week​, outlining a number of current good manufacturing practice (cGMP) violations. 

Among the issues, the FDA noted said the poor application of aseptic processing techniques. It also questioned the design of the facility, suggesting it could represent a contamination risk.

“For example, we observed an employee crawling under filling equipment to get to the area where he performed other critical operations.”

The Agency also cited an example of water from the bottom of an ISO 5 (Grade A) filling machine being collected with a cup on the ground and used to lubricate equipment.

Other violations included failures to establish laboratory controls, the use of unreliable environmental monitoring (EM) and personnel monitoring (PM) data for aseptic operations. The FDA also reported observations of poor documentation practices during production and in-process testing.

Emcure’s cGMP violation record

The facility has a history of compliance problems. 

In 2014​, nearly 23,000 bottles of methyldopa tablets made at the site for generics giant Teva were recalled after it was discovered that laboratory testing was not being conducted in accordance with cGMP.

And in February 2015​, two lots of Sagent’s Atracurium Besylate – an injectable agent used during surgery - also made at the plant were recalled. Sagent respnded by taking production in-house.

Months later, the FDA imposed an import alert​ on the facility that banned Emcure from shipping nearly all drugs made there to the US.

Emcure did not respond to requests for comment from this publication.

Related news

Show more

Related products

show more

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers